SAN DIEGO, Nov. 24, 2015 /PRNewswire/ -- Arena
Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that the
company is scheduled to present a corporate overview and update at
the Piper Jaffray 27th Annual Healthcare Conference on
Wednesday, December 2, 2015, at
8:30 a.m. Eastern Time (5:30 a.m. Pacific Time), at The New York Palace
Hotel in New York City.
A live audio webcast of the presentation will be available under
the investor relations section of Arena's website at
www.arenapharm.com. A replay of the presentation will be available
for 30 days following the event. Please connect to Arena's website
several minutes prior to the start of the webcast to ensure
adequate time for any software download that may be necessary.
About Arena Pharmaceuticals
Arena embraces the challenge of improving health by seeking to
bring innovative medicines targeting G protein-coupled receptors to
patients. Arena's focus is discovering, developing and
commercializing drugs to address unmet medical needs, and
BELVIQ® (lorcaserin HCl) is Arena's first internally
discovered drug approved for marketing. Arena has US operations
located in San Diego, California, and operations outside of the
United States, including its
commercial manufacturing facility, located in Zofingen,
Switzerland. For more information,
visit Arena's website at www.arenapharm.com.
Arena Pharmaceuticals® and Arena® are
registered service marks of Arena Pharmaceuticals, Inc.
BELVIQ® is a registered trademark of Arena
Pharmaceuticals GmbH.
Forward-Looking Statements
Certain statements in this press release are forward-looking
statements that involve a number of risks and uncertainties. Such
forward-looking statements include statements about Arena's
presentation at a conference; embracing the challenge of improving
health; seeking to bring innovative medicines to patients; and
Arena's focus, plans, goals, strategy, expectations, research and
development programs, and ability to discover and develop compounds
and commercialize drugs. For such statements, Arena claims the
protection of the Private Securities Litigation Reform Act of 1995.
Actual events or results may differ materially from Arena's
expectations. Factors that could cause actual results to differ
materially from the forward-looking statements include, but are not
limited to, the following: risks related to commercializing drugs,
including regulatory, manufacturing, supply and marketing issues
and the availability and use of BELVIQ or lorcaserin; cash and
revenues generated from BELVIQ; the risk that Arena's revenues are
based in part on estimates, judgment and accounting policies, and
incorrect estimates or disagreement regarding estimates or
accounting policies may result in changes to Arena's guidance or
previously reported results; the timing and outcome of regulatory
review is uncertain, and lorcaserin may not receive any additional
marketing approvals; regulatory decisions in one territory may
impact other regulatory decisions and Arena's business prospects;
government and commercial reimbursement and pricing decisions;
risks related to relying on collaborative arrangements; the timing
and receipt of payments and fees, if any, from collaborators; the
entry into or modification or termination of collaborative
arrangements; unexpected or unfavorable new data; nonclinical and
clinical data is voluminous and detailed, and regulatory agencies
may interpret or weigh the importance of data differently and reach
different conclusions than Arena or others, request additional
information, have additional recommendations or change their
guidance or requirements before or after approval; data and other
information related to any of Arena's research and development may
not meet regulatory requirements or otherwise be sufficient for (or
Arena or a collaborator may not pursue) further research and
development, regulatory review or approval or continued marketing;
Arena's and third parties' intellectual property rights; the
timing, success and cost of Arena's research and development and
related strategy and decisions; results of clinical trials and
other studies are subject to different interpretations and may not
be predictive of future results; clinical trials and other studies
may not proceed at the time or in the manner expected or at all;
having adequate funds; and satisfactory resolution of litigation or
other disagreements with others. Additional factors that could
cause actual results to differ materially from those stated or
implied by Arena's forward-looking statements are disclosed in
Arena's filings with the Securities and Exchange Commission. These
forward-looking statements represent Arena's judgment as of the
time of this release. Arena disclaims any intent or obligation to
update these forward-looking statements, other than as may be
required under applicable law.
Contact: Arena
Pharmaceuticals,
Inc.
|
|
Craig M. Audet,
Ph.D., Senior Vice President,
Operations & Head of Global Regulatory Affairs
caudet@arenapharm.com
858.453.7200, ext. 1612
|
|
www.arenapharm.com
|
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/arena-pharmaceuticals-to-present-at-piper-jaffray-27th-annual-healthcare-conference-300183677.html
SOURCE Arena Pharmaceuticals, Inc.